Endocrine Abstracts

Castration-resistant prostate cancer (CRPC) develops after androgen deprivation therapy of advanced PC, often with metastatic growth in bone and very poor prognosis. Standard treatment is docetaxel, followed by androgen-synthesis (abiraterone) or androgen receptor inhibition, or treatment with the novel taxane cabazitaxel. Novel drugs are constantly under development and molecular properties of individual tumors will determine treatment effectiveness in individual cases. The a...

The relation between androgen receptor (AR) gene amplification and other mechanisms behind castration-resistance in prostate cancer, such as increased expression of constitutively active AR variants and steroid-converting enzymes have been poorly examined. Specific aims of this study were to examine AR amplification in treatment-naïve and castration-resistant prostate cancer (CRPC) bone metastases and to explore molecular and functional differences. AR gene amplification ...